Plain-English translation of NCT07455188 on ClinicalTrials.gov ↗ ·
This trial is testing what happens when patients with a specific type of advanced breast cancer switch between two different drug treatment combinations. One combination uses trastuzumab with chemotherapy, and the other uses pyrotinib with chemotherapy. The study wants to understand which approach—or which order of switching—works best for patients whose cancer has stopped responding to their first treatment.
When breast cancer spreads and stops responding to the first treatment, doctors need to know the best second option. This study is designed to compare two different switching strategies to help doctors make better treatment decisions for patients in this situation.
You likely qualify if…
You likely don't qualify if…
You would receive one of the two drug combinations as your first treatment in the study. If your cancer progresses or you cannot tolerate this treatment, you would switch to the other combination as your second treatment. You'll visit the research center every two treatment cycles (roughly every 4–6 weeks) for check-ups, blood tests, imaging scans, and to report any side effects. You'll continue treatment until your cancer progresses, side effects become too severe, or your doctor decides to stop for another reason. The entire study follows you through initial screening, two treatment phases, and a follow-up period to track your health.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China